Peptide expression construct and its use
By integrating a destabilization domain and translation separator into nucleic acid molecules, the expression and effectiveness of short peptides as PPI modulators are enhanced, overcoming limitations of biological availability and solubility.
Patent Information
- Application Number
- JP2025553704
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-15
- Filing Date
- 2024-03-14
- Publication Date
- 2026-03-19
AI Technical Summary
Existing short peptides face challenges such as limited biological availability, low solubility, and poor membrane permeability when used as protein-protein interaction (PPI) modulators, and intracellular expression of short peptides is hindered by decreased ribosome binding with shorter coding sequences.
Incorporation of a destabilization domain (DD) and a translation separator, such as the self-cleaving peptide P2A, into nucleic acid molecules encoding short peptides, facilitating their intracellular expression by acting as a ribosome-binding fragment and stabilizing the target peptide.
Enhances the expression of target peptides within cells, improving their effectiveness as PPI modulators by increasing stability and membrane permeability, thereby addressing the limitations of existing peptide therapies.